依拉克托辛的I期试验。
Phase I trial of elactocin.
作者信息
Newlands E S, Rustin G J, Brampton M H
机构信息
Department of Medical Oncology, Charing Cross Hospital, London, UK.
出版信息
Br J Cancer. 1996 Aug;74(4):648-9. doi: 10.1038/bjc.1996.415.
Abstract
Elactocin is a novel anti-tumour antibiotic which has potent activity in vitro against a range of tumours. This phase I trial of elactocin identified the dose-limiting toxicity as profound anorexia and malaise. The schedules used included 1 h infusion 3 weekly, 24 h infusion 3 weekly, 1 h infusion daily x 5 (3 weekly), 1 h infusion weekly and finally continuous 5 day intravenous infusion. On all these schedules dose-limiting toxicity was the same and as no partial or complete responses were identified, we do not recommend that further trials of elactocin are performed.
摘要
伊拉托星是一种新型抗肿瘤抗生素，在体外对一系列肿瘤具有强效活性。伊拉托星的这一I期试验确定剂量限制性毒性为严重厌食和不适。所采用的给药方案包括每3周1小时输注、每3周24小时输注、每天1小时输注×5天（每3周）、每周1小时输注，最后是连续5天静脉输注。在所有这些给药方案中，剂量限制性毒性相同，且由于未发现部分或完全缓解，我们不建议对伊拉托星进行进一步试验。
相似文献
1
Phase I trial of elactocin.依拉克托辛的I期试验。
Br J Cancer. 1996 Aug;74(4):648-9. doi: 10.1038/bjc.1996.415.
2
3
Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors.卡哈利德 F 每周作为延长输注治疗晚期实体瘤患者的 I 期研究。
Cancer Chemother Pharmacol. 2013 Jul;72(1):75-83. doi: 10.1007/s00280-013-2170-5. Epub 2013 May 5.
4
5
Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.S9788（一种新型多药耐药逆转剂）单独及与阿霉素联合应用于晚期实体瘤患者的I期临床和药代动力学研究。
Cancer Chemother Pharmacol. 1998;41(4):281-91. doi: 10.1007/s002800050741.
6
Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.96小时持续输注右丙亚胺与剂量密集型阿霉素同步给药治疗晚期恶性肿瘤的可行性及药代动力学研究
Cancer Chemother Pharmacol. 2004 Sep;54(3):241-8. doi: 10.1007/s00280-004-0803-4. Epub 2004 Jun 2.
7
Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.多西他赛与持续静脉输注拓扑替康用于晚期恶性肿瘤患者的I期剂量递增及序贯研究。
Cancer Chemother Pharmacol. 2005 Aug;56(2):182-8. doi: 10.1007/s00280-004-0925-8. Epub 2005 Apr 19.
8
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.法尼基转移酶抑制剂BMS-214662在晚期实体瘤患者中进行的I期临床试验，给药方式为每周一次24小时持续静脉输注。
Cancer Chemother Pharmacol. 2006 Jul;58(1):107-16. doi: 10.1007/s00280-005-0134-0. Epub 2005 Dec 13.
9
A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.一项使用24小时静脉输注对晚期恶性肿瘤患者进行的布立他汀1的I期试验。
Br J Cancer. 1995 Aug;72(2):461-8. doi: 10.1038/bjc.1995.356.
10
Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.72小时持续输注紫杉醇，随后静脉推注异环磷酰胺或表柔比星：两项I期研究的结果。
Oncology. 2001;60(2):116-22. doi: 10.1159/000055307.
引用本文的文献
1
Selinexor in acute myeloid leukemia: therapeutic applications and current challenges.塞利尼索在急性髓系白血病中的应用：治疗作用与当前挑战
Front Pharmacol. 2025 May 20;16:1602911. doi: 10.3389/fphar.2025.1602911. eCollection 2025.
2
Modulation of anti-tumour immunity by XPO1 inhibitors.XPO1抑制剂对抗肿瘤免疫的调节作用。
Explor Target Antitumor Ther. 2025 Apr 23;6:1002310. doi: 10.37349/etat.2025.1002310. eCollection 2025.
3
XPO1-dependency of DEK::NUP214 leukemia.DEK::NUP214白血病对XPO1的依赖性
Leukemia. 2025 May;39(5):1102-1113. doi: 10.1038/s41375-025-02570-1. Epub 2025 Mar 27.
4
Effect of Exportin 1/XPO1 Nuclear Export Pathway Inhibition on Coronavirus Replication.输出蛋白1/ XPO1核输出途径抑制对冠状病毒复制的影响。
Viruses. 2025 Feb 18;17(2):284. doi: 10.3390/v17020284.
5
Strategies for the Viral Exploitation of Nuclear Pore Transport Pathways.病毒利用核孔运输途径的策略。
Viruses. 2025 Jan 23;17(2):151. doi: 10.3390/v17020151.
6
Targeting CRM1 for Progeria Syndrome Therapy.靶向CRM1用于早衰综合征治疗。
Aging Cell. 2025 May;24(5):e14495. doi: 10.1111/acel.14495. Epub 2025 Jan 27.
7
Prognostic and functional role of the nuclear export receptor 1 (XPO1) in gastrointestinal cancers: a potential novel target?核输出受体1（XPO1）在胃肠道癌症中的预后和功能作用：一个潜在的新靶点？
Mol Biol Rep. 2024 Dec 27;52(1):87. doi: 10.1007/s11033-024-10169-5.
8
Therapeutic targeting of exportin-1 beyond nuclear export.除核输出外对输出蛋白-1的治疗性靶向作用
Trends Pharmacol Sci. 2025 Jan;46(1):20-31. doi: 10.1016/j.tips.2024.11.002. Epub 2024 Dec 5.
9
Novel-and Not So Novel-Inhibitors of the Multifunctional CRM1 Protein.多功能CRM1蛋白的新型及非新型抑制剂
Oncol Rev. 2024 Aug 5;18:1427497. doi: 10.3389/or.2024.1427497. eCollection 2024.
10
Targeting of nucleo‑cytoplasmic transport factor exportin 1 in malignancy (Review).恶性肿瘤中核质转运因子输出蛋白1的靶向作用（综述）
Med Int (Lond). 2021 Dec 28;2(1):2. doi: 10.3892/mi.2021.27. eCollection 2022 Jan-Feb.
本文引用的文献
1
Anticancer activity of the structurally novel antibiotic Cl-920 and its analogues.
Cancer Res. 1984 May;44(5):1928-32.
2
Novel antitumor antibiotics, CI-940 (PD 114,720) and PD 114,721. Taxonomy, fermentation and biological activity.新型抗肿瘤抗生素CI-940（PD 114,720）和PD 114,721。分类学、发酵及生物活性。
J Antibiot (Tokyo). 1985 Apr;38(4):460-5. doi: 10.7164/antibiotics.38.460.
3
In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721).结构新颖且高效的抗生素CI-940及其羟基类似物（PD 114,721）的体内和体外抗癌活性
Cancer Chemother Pharmacol. 1986;16(2):95-101. doi: 10.1007/BF00256156.
Zotero 插件